The FTC Launches a Dedicated Healthcare Task Force

Why It Matters

The task force signals a heightened federal commitment to policing anticompetitive behavior and deceptive practices in health care, which could lower costs and improve transparency for patients and providers.

Key Takeaways

• FTC creates first integrated healthcare enforcement unit.
• Task force merges antitrust and consumer protection efforts.
• Includes DOJ, HHS, and FTC technology offices.
• Targets PBM, device, billing, and privacy abuses.
• Aims to increase transparency and lower patient costs.

Pulse Analysis

The FTC’s decision to form a dedicated Healthcare Task Force reflects a broader shift toward aggressive oversight of a sector long plagued by consolidation. Rising drug prices, opaque billing practices, and the dominance of pharmacy‑benefit managers have drawn bipartisan concern, prompting the 2025 executive order that called for clearer pricing information. By consolidating antitrust and consumer‑protection expertise, the FTC aims to move beyond piecemeal investigations and develop a coordinated playbook that can address complex, multi‑jurisdictional violations more efficiently.

Structurally, the task force brings together senior officials from the Bureaus of Competition and Consumer Protection, while also tapping resources from the Department of Justice, the Department of Health and Human Services, and internal FTC units such as Technology and Policy Planning. This inter‑agency model mirrors successful collaborations in other sectors, allowing the FTC to leverage DOJ’s litigation muscle, HHS’s data assets, and its own economic analysis capabilities. Recent FTC actions against pharmacy‑benefit managers and deceptive medical‑device marketing illustrate the kind of high‑stakes cases the new unit is poised to pursue, with a focus on both price‑fixing schemes and misleading consumer communications.

For industry participants, the task force could herald stricter scrutiny of mergers, pricing algorithms, and patient‑data practices. Companies may need to bolster compliance programs, increase transparency in contracts, and prepare for more frequent amicus briefs or statements of interest. While the task force will not fundamentally alter the FTC’s existing review of provider transactions, its broader mandate to scan emerging issues—such as telehealth platforms and health‑tech data aggregators—suggests a future where antitrust and consumer‑protection lenses are applied simultaneously, potentially reshaping market dynamics and delivering tangible savings to American patients.